ACM Global Relocates to Expanded Lab Facilities in Europe
ACM Global Central Laboratory
, the central laboratory that continually defines the customer-service standard with its flexible approach, today announced that it has relocated its laboratory facilities in York, England. The move to a larger facility is in response to growing client demand for ACM Global’s clinical trials testing services throughout Europe, including Western and Eastern Europe, as well as South Africa and the Middle East.
The new, state-of-the-art facility offers 14,500 square feet of laboratory and office space, nearly twice the size of ACM Global’s previous facility in York, and accommodates ACM Global’s expanding laboratory operations as well as its growing staff of data analysts, project managers and quality assurance specialists.
“Our new facility enables us to continue our growth in the European market and to expand the menu of clinical trials testing services we offer our clients,” said Jerry Boxall, Managing Director, Europe at ACM Global Central Laboratory. “We are excited with the prospects offered by our new facility, which has been purpose-built to optimize our laboratory processes. The additional space enhances our ability to continue to meet the needs of our clients with high-quality laboratory services, while positioning us to take advantage of new opportunities in the market.”
“Expansion of our European laboratory hub represents a significant investment by our company, driven by our growth over the last several years”, said Angela J. Panzarella, President of ACM Medical Laboratory, Incorporated, the parent company of ACM Global Central Laboratory. “We have enjoyed robust growth in our European and global business, and the new facility represents our commitment to the region and to continuous improvement of the services we offer our clients.”
To celebrate its new laboratory location, ACM Global will host a grand opening and ribbon-cutting event on Thursday, January 17, 2013 at the new facility, located at 23 Hospital Fields Road in York. Current and prospective clients are invited to attend the day-long event, which will include tours of the facility, a workshop and an evening reception. For questions regarding the relocation or to attend the grand opening, please visit
http://www.acmgloballab.com/yorkrelocationfaq.aspx
.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
